Click on a filter below to refine your search. Remove a filter to broaden your search.
The mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab or placebo.
A small improvement seen in global cognition scores, but it was no different from those following control diet with mild caloric restriction.